EVQLV develops artificial intelligence, engineered with life science data, to accelerate how biologic therapies reach patients. They work with partners at the discovery stage to accelerate the speed of antibody discovery.

Biotechnology

EVQLV

Andrew Satz

Matthew K. Fox

Jeff Snell

Ben Maida

Alexander Sonneborn

Richard Fox

Brett Averso

The Advisory Team at EVQLV consists of seasoned experts who provide strategic guidance and insights to optimize the use of artificial intelligence in accelerating antibody discovery. They collaborate with partners to identify opportunities, mitigate risks, and enhance the efficacy and speed of biologic therapy development.

Advisory Team

Leadership Team

Advisory Team

About

Team members

Other teams at EVQLV

Leadership Team